DalsnaFinance

Idexx Laboratories $IDXX

Health Care · Health Care Equipment · NASDAQ

S&P 500 Nasdaq-100 Russell 1000 Maine
Create a scorecard
$556.87
+1.07 (+0.19%)
As of Oct 20, 2026, 11:22 AM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 18, 2026, the first target we tracked for IDXX.

Key facts

52-week range (closes)
$504.70 – $766.68 Lowest close Sep 11, 2026, highest Nov 25, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings
Nov 2, 2026, before the open · EPS forecast $3.70 Nasdaq earnings calendar, as of Oct 20, 2026
Fiscal year ends
December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since
Jan 5, 2017, replacing St Jude Medical (STJ) · Abbott Laboratories acquired St. Jude Medical. · All S&P 500 changes
In the Nasdaq-100 since
Mar 20, 2017, replacing SBA Communications (SBAC) · SBA converted into a real estate investment trust, making it ineligible for inclusion in the Nasdaq-100, but it became eligible for inclusion in the Nasdaq Financial-100. · All Nasdaq-100 changes
Analyst coverage
1 open price target from 1 firm: Stifel Approved targets tracked here; see the analyst section below

Idexx Laboratories (IDXX) is trading up at $556.87 (+0.19%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on IDXX

One firm's current price target on Idexx Laboratories: $675 — 21% above the current $557. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Idexx Laboratories revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$4.30B$2.15B$0FY2016 revenue: $1.78BFY2016 net income: $222.0M · Net margin 12.5%'16FY2017 revenue: $1.97BFY2017 net income: $263.1M · Net margin 13.4%'17FY2018 revenue: $2.21BFY2018 net income: $377.0M · Net margin 17.0%'18FY2019 revenue: $2.41BFY2019 net income: $427.7M · Net margin 17.8%'19FY2020 revenue: $2.71BFY2020 net income: $581.8M · Net margin 21.5%'20FY2021 revenue: $3.22BFY2021 net income: $744.8M · Net margin 23.2%'21FY2022 revenue: $3.37BFY2022 net income: $679.1M · Net margin 20.2%'22FY2023 revenue: $3.66BFY2023 net income: $845.0M · Net margin 23.1%'23FY2024 revenue: $3.90BFY2024 net income: $887.9M · Net margin 22.8%'24FY2025 revenue: $4.30BFY2025 net income: $1.06B · Net margin 24.6%'250%10%20%30%FY2016 net margin: 12.5%FY2017 net margin: 13.4%FY2018 net margin: 17.0%FY2019 net margin: 17.8%FY2020 net margin: 21.5%FY2021 net margin: 23.2%FY2022 net margin: 20.2%FY2023 net margin: 23.1%FY2024 net margin: 22.8%FY2025 net margin: 24.6%
Idexx Laboratories annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.78B$1.97B$2.21B$2.41B$2.71B$3.22B$3.37B$3.66B$3.90B$4.30B
Growth (year over year)+10.8%+10.9%+12.4%+8.8%+12.5%+18.8%+4.7%+8.7%+6.5%+10.4%
Gross profit$975.4M$1.10B$1.24B$1.37B$1.57B$1.89B$2.00B$2.19B$2.38B$2.66B
Gross margin54.9%55.7%56.1%56.7%58.0%58.8%59.5%59.8%61.0%61.8%
Operating income$350.2M$413.0M$491.3M$552.8M$694.5M$932.0M$898.8M$1.10B$1.13B$1.36B
Operating margin19.7%21.0%22.2%23.0%25.7%29.0%26.7%30.0%29.0%31.6%
Net income$222.0M$263.1M$377.0M$427.7M$581.8M$744.8M$679.1M$845.0M$887.9M$1.06B
Net margin12.5%13.4%17.0%17.8%21.5%23.2%20.2%23.1%22.8%24.6%
EPS (diluted)$2.44$2.94$4.26$4.89$6.71$8.60$8.03$10.06$10.67$13.08
Balance sheet
Cash and equivalents$154.9M$187.7M$123.8M$90.3M$383.9M$144.5M$112.5M$453.9M$288.3M$180.1M
Total assets$1.53B$1.74B$1.62B$1.83B$2.29B$2.44B$2.75B$3.26B$3.29B$3.35B
Total liabilities$1.64B$1.80B$1.63B$1.65B$1.66B$1.75B$2.14B$1.78B$1.70B$1.75B
Long-term debt$593.7M$606.6M$601.8M$698.9M$858.5M$775.2M$694.4M$622.9M$449.8M$374.8M
Shareholders' equity−$108.4M−$54.1M−$9.51M$177.5M$632.1M$690.0M$608.7M$1.48B$1.60B$1.61B
Cash flow
Operating cash flow$338.9M$373.3M$400.1M$459.2M$648.1M$755.5M$543.0M$906.5M$929.0M$1.18B
Capital expenditure$64.8M$74.4M$115.8M$155.0M$107.0M$119.5M$148.8M$133.6M$120.9M$124.7M
Free cash flow$274.2M$298.9M$284.3M$304.2M$541.1M$636.0M$394.1M$772.9M$808.1M$1.06B
Share buybacks$304.1M$282.6M$369.3M$301.7M$182.8M$746.8M$819.7M$71.9M$837.0M$1.22B

From Idexx Laboratories's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Idexx Laboratories vs the Health Care sector and the S&P 500

Idexx Laboratories's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Idexx Laboratories compared with the median Health Care company and the median S&P 500 company
MeasureIdexx LaboratoriesHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year+10.4%+7.1%+7.0%
Net margin, latest fiscal year24.6%12.9%12.9%
Share price change, 1 year−13.6%+19.8%+5.9%

Idexx Laboratories: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Idexx Laboratories included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Idexx Laboratories

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions.

Source: Wikipedia — Idexx Laboratories

Headquarters
Westbrook, Maine From SEC filings, Oct 2026

Recent News (15)

More Health Care stocks

Browse all companies →